This review highlights the diverse cardiovascular toxicities associated with modern cancer therapies and emphasizes the need for appropriate monitoring and management strategies.
Answers are grounded in this paper and cite their sources.
Requires cardiotoxicity surveillance during cancer therapy; leaves open optimal genetic and route-specific risk mitigation strategies.
Modern cancer therapy employs a combination of chemotherapy, antibody-based therapy, radiotherapy, and surgery to prolong life and provide cure. However, many of the chemotherapy agents and antibodies, either singly or in combination, can affect the cardiovascular system. Common cardiovascular manifestations of these therapies include heart failure, ischemia, hypotension, hypertension, edema, QT prolongation, bradyarrhythmia, and thromboembolism. The patient's age, underlying cardiovascular status, and genetic background, as well as the route of drug administration and dosage, can all contribute to the development of cardiotoxicity. Strategies to monitor for and to manage these effects are discussed in this review.
No takes yet. Share an insight, caveat, or question.
Edward T.H. Yeh (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: